G
lutamate receptor activation has a major role in the development of ischemic damage in cerebral tissue. 12 During focal cerebral ischemia, neurotoxic levels of glutamate and aspartate (typically peaking 1 hour after occlusion) have been detected in the extracellular space by microdialysis techniques. 3 ' 4 Based on electrophysiological studies, postsynaptic receptors for the excitatory amino acids are classified into four main subtypes. 5 These comprise the /V-methyl-r> aspartate (NMDA)-, the kainate (KA)-, and the S-aamino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) (formerly quisqualate)-preferring receptors and the glutamate metabotropic (or 1-amino-cyclopentane-rratts-dicarboxylate) receptor. The AMPA and KA receptors may be grouped collectively as "non-NMDA receptors." The excitotoxic effect of glutamate has been extensively reported both in vivo and in vitro and acts via the NMDA or non-NMDA receptors. 6 -7 Cerebroprotection with NMDA antagonists has been well documented after focal cerebral ischemia.
2 -8 - 13 Tarnawa and coworkers 14 ' 15 have recently described a novel non-NMDA antagonist, GYKI 52466 (l-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; molecular weight, 330), which inhibits spinal reflexes in cats but does not potentiate the inhibitory action of y-amino butyrate. Ouardouz and Durand 16 have shown that GYKI 52466 antagonizes the glutamate-but not the NMDA-or KA-induced electrophysiological responses in the abducens motor neurons of the rat. A concentration of 10-50 fiM GYKI 52466 considerably attenuates the quisqualate-but not the NMDA-induced neuronal depolarization in rat somatosensory cortical slices. 15 Two minutes after an intravenous dose of [ M C]GYKI 52466 (12 fimol • kg" 1 ), a 20-30 fiM concentration of the drug can be detected in the rat brain. 17 Systemic administration of a higher dose of GYKI 52466 (60 /imol • kg" 1 i.v.) selectively blocks ./?,S-AMPA-induced seizures (dose ratio, 9.1) and to a lesser extent KA-induced seizures (dose ratio, 2.9) but not NMDA-induced seizures (dose ratio, 1.3) in mice. 18 The time course for the anticonvulsant effect for GYKI 52466 in mice, rats, and baboons is very short (from 5 to 60 minutes) after intraperitoneal or intravenous administration. 19 -20 The present study was designed to determine whether the non-NMDA antagonist GYKI 52466 has cerebroprotective effects after permanent left middle cerebral artery (MCA) occlusion in the rat. Values are mean infarct volumes in cubic millimeters (±SD).
Materials and Methods
Adult male Fischer F344 rats weighing 210-310 g were housed in groups of four to six in poh/vinylchloride cages (350 mm widex530 mm Iongxl80 mm high) in an environment maintained at 19-22°C and a relative humidity of 55±3% with a 14-hour/10-hour light/dark cycle (light on from 6 AM to 8 PM). Food and water were available ad libitum. Halothane was used to induce (4% in a mixture of 70% N 2 O and 30% O 2 ) and maintain (2%) anesthesia. Each rat was allowed to breathe spontaneously, and rectal temperature was maintained at 37°C (36.5-38°C) with a heating blanket. In some experiments, the left femoral vein was cannulated for drug administration and the caudal (tail) artery was cannulated for the continuous monitoring of arterial blood pressure, repeated blood sampling for serial measurements of blood glucose concentration, Pao^ Pacc^, and pH levels. Blood gases were analyzed using an IL13404 analyzer (Instrumentation Laboratories, Cheshire, UK), and blood glucose was measured with Glucostix strips (Bayer Diagnostics, Ames Division, Slough, UK). Inner ear temperature and temporalis muscle temperature were monitored using thermoprobes.
All animals underwent subtemporal subperiosteal craniectomy (with intact zygoma) and exposure of the main trunk of the left MCA under 25-fold magnification of an operating stereomicroscope. 21 - 22 The exposed artery was electrocauterized from its origin (including the lenticulostriate branch[es]) to its junction with the inferior cerebral vein.
Animals received three injections of GYKI 52466 (10 mg • kg" 1 i.p. at 0, 2, and 4 hours) or vehicle (highperformance liquid chromatography water) (5 ml • kg" 1 ) at 0, 2, and 4 hours after occlusion. In a further study, the animals received a loading infusion of 10 mg • kg" 1 (2 ml • kg" 1 over a 5-minute period) of either GYKI 52466 or vehicle (0.2 ml ethanol/3.8 ml high-performance liquid chromatography water) followed by an infusion of 15 mg • kg" 1 • hr" 1 (3 ml • kg" 1 ) for 2 hours immediately after, 1 hour after, or 2 hours after occlusion. During the 1-and 2-hour delays and the 2-hour infusions, animals were lightly anesthetized with 0.5% halothane in a mixture of 70% N 2 O and 30% O 2 .
Twenty-four hours after MCA occlusion, the rats were assessed in a blinded fashion for neurological deficits based on the rating scales used by Bederson et al 23 and Germano et al. 8 The following grading scale was used: Grade 0, no observable deficit; grade 1, forelimb flexion; grade 2, forelimb flexion and decreased resistance to lateral push; and grade 3, forelimb flexion, decreased resistance to lateral push, and severe circling. The animals were then decapitated using a guillotine, and the brain was rapidly removed (within 2 minutes), examined for proximal MCA occlusion, and then placed into a vibrotome containing saline at 8°C. Ten coronal sections (1 mm thick) were cut from the frontal pole and then incubated for 30 minutes in microwells, each of which contained 2 ml 2% (wt/vol) triphenyltetrazolium chloride in saline at 37°C before storage in 0.1 M phosphate-buffered (pH 7.4) 5% (vol/vol) formaldehyde in saline for 1-5 days. The sections were photographed to scale, and slides were prepared and used to estimate the left and right hemispheric and the total, cortical, and noncortical infarct areas using an IBAS image analyzer (Kontron Elektronik, GmbH, Eching, FRG). These areas were used to calculate the hemispheric and infarct volumes in terms of cubic millimeters by use of a BASIC integration program that is based on the ends of spheres and truncated cones. Results are expressed as mean±SD and were analyzed using Student's unpaired / test.
Results
There was a consistent pattern of ischemic brain damage after permanent MCA occlusion. Lesions were seen in the dorsolateral frontoparietal cortex, the caudatoputamen, and the globus pallidus. The boundaries between the areas of infarction and the normal adjacent areas were sharply demarcated.
GYKI 52466 (10 mg • kg" 1 i.p. at 0, 2, and 4 hours) had no effect on infarct volume compared with that in vehicle-treated control rats (see Table 1 ). In these groups rectal temperature was maintained between 36.5 C C and 38°C. Neurological deficits were not studied. Infusion (0-2-hour) of GYKI 52466 (10 mg • kg" 1 i.v. for 5 minutes followed by 15 mg • kg' 1 • hr" 1 for 2 hours) immediately after occlusion reduced the total infarct volume by 53% (from 152±51 mm 3 in vehicle-treated rats to 71 ±43 mm 3 in GYKI 52466-treated animals; p<0.05). Cortical infarct volume was reduced by 68% (from 69±17 mm 3 in vehicle-treated rats to 22±11 mm 3 in GYKI 52466-treated animals; p<0.05) (see Figure  1 ). Neurological deficit was also reduced (see Figure 2 ; vehicle score, 2.1±0.4; GYKI 52466 score, 1.5±0.7; p<0.05). There were no significant changes in mean arterial blood pressure or rectal temperature («=8). All other values were within normal ranges. Delayed (1-hour) postocclusion infusion (1-3 hours) of GYKI 52466 (10 mg • kg" 1 i.v. for 5 minutes followed by 15 mg • kg" 1 • hr" 1 for 2 hours) reduced cortical infarct volume by 48% (from 60±27 mm 3 in vehicletreated rats to 31 ±16 mm 3 in GYKI 52466-treated animals; p<0.05) (see Figure 1) . Neurological deficit was also reduced (see Figure 2; Delayed (2-hour) postocclusion infusion (2-4 hours) of GYKI 52466 (10 mg • kg" 1 i.v. for 5 minutes followed by 15 mg • kg" 1 • hr" 1 for 2 hours) had no effect on infarct volume compared with vehicle-treated control rats (see Figure 1) . However, neurological deficit was reduced (see Figure 2 ; vehicle score, 2.3+0.5; GYKI 52466 score, 1.5±0.5; p<0.05). A significant reduction of 10 mm Hg in mean arterial blood pressure was observed after the rapid loading infusion of GYKI 52466 (10 mg • kg" 1 i.v.) 120-125 minutes after the MCA occlusion (p<0.05, Student's paired t test). A return to baseline mean arterial blood pressure occurred within 10 minutes of this effect. All other values were within normal ranges. On recovery from anesthesia the animals displayed no behavioral side effects after the 2-hour infusion of GYKI 52466. Hemispheric volumes for the infusion studies are included in Table 2 for purpose of review. For all groups rectal and inner ear temperatures were similar, ranging between 37.1°C and 37.7°C and 36.7°C and 36.9°C, respectively. The temporalis temperature was lower, ranging between 29.4°C and 33.2°C. Discussion GYKI 52466 reduces cortical infarct volume in rats when administered within 1 hour and improves neurological deficit when administered 0-2 hours after the ischemic insult. This therapeutic window for the cerebroprotective effect coincides with the peak increase of neurotoxic levels of glutamate and aspartate, which occurs 1 hour after occlusion during focal cerebral ischemia. 34 A similar regimen of GYKI 52466 infusion (30 mg • kg" 1 over 3 hours) selectively protects against the excitotoxic effects of kainate (but not NMD A) when focally injected into the hippocampus 24 and reduces cell degeneration in the cortex Values are mean hemispheric volumes in cubic millimeters (±SD).
•Significantly smaller than the left hemisphere of vehicletreated animals (p<0.05).
tSignificantly smaller than the left hemisphere of GYKI 52466-treated animals (p<0.05). and striatum after four-vessel occlusion in the rat. 27 GYKI 52466 is a hydrophobic compound and has a fast onset of action and short-lived anticonvulsant effects in mice, rats, and baboons 19 -20 ; therefore, these factors necessitate a continuous intravenous infusion of GYKI 52466 after the ischemic insult to observe a cerebroprotective effect. Two very recent reports describe the cortical cerebroprotective effects of another non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(/^-quinoxaline (NBQX), and its administration (30 mg • kg"" 1 i.v. at 0 and 60 minutes 26 or 30 mg-kg" 1 i.p. at 90, 120, and 180 minutes 27 ) after permanent MCA occlusion in the rat. NBQX has a greater binding affinity for the AMPA than for the KA receptor and little or no affinity for the NMDA or the NMDA-glycine site. 28 Results from binding studies for GYKI 52466 are not yet available. It has, however, been clearly demonstrated electrophysiologically that GYKI 52466 has selective non-NMDA versus NMDA antagonist properties at the doses used in this study. Thus, activation of non-NMDA receptors by glutamate appears to contribute to the infarction process after permanent MCA occlusion in the area of the ischemic penumbra. Blockade of glutamatergic neurotransmission at sites distant from the ischemic focus may also contribute to cerebroprotection. 2 The GYKI 52466-induced reduction of mean arterial blood pressure by 10 mm Hg (in the group of animals that received delayed administration) is unlikely to have contributed to the cerebroprotective effect. Comparable degrees of cerebroprotection have been observed with competitive NMDA, noncompetitive NMDA, and non-NMDA antagonists after focal cerebral ischemia in rats. - 27 Of these classes of excitatory amino acid antagonists, the noncompetitive NMDA antagonists have the lowest therapeutic indexes in experimental animals. There were no adverse behavioral side effects observed after GYKI 52466 administration to rats in the present study. In mice GYKI 52466 and NBQX have therapeutic indexes of 2 and 6.6, respectively (where the therapeutic index is the median effective dose [ED 50 ] for ataxia divided by the ED 50 for an anticonvulsant effect). 19 From the physician's and patient's standpoint, a drug for the therapy of stroke needs to have a therapeutic index as high as possible, thus favoring competitive NMDA or non-NMDA antagonists as potential candidates for clinical trials. The case for a clinical trial of NMDA antagonists in stroke has been clearly stated. 13 Further studies are required with non-NMDA antagonists before their clinical potential and relative merits compared with NMDA antagonists can be defined.
